Injury effect of σ1R agonists on ICa kinetics
Sample size: n = 6–8 for Gmax, activation and inactivation, n = 10–13 for inactivation kinetics; mean ± S.E.M.
| PTZ | DTG | |||
|---|---|---|---|---|
| Control | SNL | Control | SNL | |
| Gmax (change, %) | −25.8 ± 11.3 | −30.7 ± 5.3 | −30.5 ± 4.3 | −31.9 ± 6.9 |
| Activation V1/2 (ΔmV) | −3.6 ± 0.6 | −4.3 ± 1.4 | −3.8 ± 1.2 | −2.2 ± 1.1 |
| Activation slope (Δ%) | −0.3 ± 9.7 | −4.3 ± 14.5 | −4.6 ± 15.6 | −24.7 ± 10.8 |
| S-S inactivation V1/2 (ΔmV) | −9.6 ± 1.6 | −8.6 ± 2.9 | −7.3 ± 1.6 | −11.6 ± 1.7* |
| S-S inactivation slope (Δ%) | 0.2 ± 3.0 | 1.0 ± 4.0 | −0.8 ± 6.4 | 6.1 ± 5.6 |
| Inactivation τ1 (Δs) | −0.02 ± 0.02 | 0.01 ± 0.01 | −0.01 ± 0.01 | −0.03 ± 0.01 |
| Inactivation τ2 (Δs) | −0.92 ± 0.22 | −0.92 ± 0.19 | −0.57 ± 0.10 | −1.09 ± 0.17* |
S-S, steady-state; V1/2, voltage at which current is half-maximal; τ, inactivation kinetic constant; Δ, difference between baseline and agonist treatment.
↵* P < 0.05.